The Drug Enforcement Administration announced this week that it was now accepting comments on a Virginia-based biotechnology company’s application to import “marihuana extract” and “tetrahydrocannabinol.”
In a small notice published in the government’s daily Federal Register report, the DEA stated that Sanyal Biotechnology was looking to import cannabis extracts and THC to use in the organization’s research on liver diseases.
According to the DEA’s Diversion Control Division, Sanyal Biotechnology is the second company this year to request to import the two cannabis-based substances. The other company, Noramco, also requested permission to import whole plant marijuana. >>>